➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Colorcon
Express Scripts
Medtronic
Baxter

Last Updated: June 25, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Sulopenem


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Sulopenem?

Sulopenem is an investigational drug.

There have been 6 clinical trials for Sulopenem. The most recent clinical trial was a Phase 2 trial, which was initiated on August 1st 2018.

The most common disease conditions in clinical trials are Infection, Communicable Diseases, and Urinary Tract Infections. The leading clinical trial sponsors are Iterum Therapeutics, US Limited, Pfizer, and Iterum Therapeutics, International Limited.

There are two hundred and thirty US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for Sulopenem
TitleSponsorPhase
Safety, Tolerability, and Pharmacokinetics of Sulopenem in AdolescentsIterum Therapeutics, International LimitedPhase 1
Oral Sulopenem Etzadroxil With Probenecid Versus Ciprofloxacin for Uncomplicated Urinary Tract Infection in Adult WomenIterum Therapeutics, US LimitedPhase 3
Sulopenem and Sulopenem Etzadroxil With Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in AdultsIterum Therapeutics, US LimitedPhase 3

See all Sulopenem clinical trials

Clinical Trial Summary for Sulopenem

Top disease conditions for Sulopenem
Top clinical trial sponsors for Sulopenem

See all Sulopenem clinical trials

US Patents for Sulopenem

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Sulopenem   Get Started Free Methods of treating inflammation associated airway diseases and viral infections WASHINGTON STATE UNIVERSITY (Pullman, WA) THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (Austin, TX)   Get Started Free
Sulopenem   Get Started Free Use of gelsolin to treat infections The Brigham and Women's Hospital, Inc. (Boston, MA)   Get Started Free
Sulopenem   Get Started Free Compositions and methods for delivering an agent to a wound UNIVERSITY OF MEMPHIS RESEARCH FOUNDATION (Memphis, TN)   Get Started Free
Sulopenem   Get Started Free Oral appliance for delivering a medicament   Get Started Free
Sulopenem   Get Started Free Genetically engineered swine influenza virus and uses thereof Icahn School of Medicine at Mount Sinai (New York, NY) St. Jude Children's Research Hospital (Memphis, TN) The United States of America, As Represented by the Secretary of Agriculture (Washington, DC)   Get Started Free
Sulopenem   Get Started Free Method for using novel hydroxamic acid derivative and antibacterial substance in combination TOYAMA CHEMICAL CO., LTD. (Shinjuku-ku, JP)   Get Started Free
Sulopenem   Get Started Free Pharmaceutical agents and methods relating thereto Cushing Academy (Ashburnham, MA)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Sulopenem

Drugname Country Document Number Estimated Expiration Related US Patent
Sulopenem Australia AU2005244865 2024-05-12   Get Started Free
Sulopenem Canada CA2607686 2024-05-12   Get Started Free
Sulopenem Canada CA2860173 2024-05-12   Get Started Free
Sulopenem China CN1980694 2024-05-12   Get Started Free
Sulopenem Denmark DK1755661 2024-05-12   Get Started Free
Sulopenem European Patent Office EP1755661 2024-05-12   Get Started Free
Sulopenem European Patent Office EP2335722 2024-05-12   Get Started Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Express Scripts
Boehringer Ingelheim
McKinsey
AstraZeneca
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.